Mezoo CEO Park Jung-hwan presented the company’s strategy and vision following its planned KOSDAQ listing at a press conference held on the 9th at the Conrad Hotel in Yeouido, Seoul. [Source: Reporter Lim Seo-a]

“Through this listing, Mezoo will combine data-driven predictive and diagnostic technologies with clinical experience to expand a digital healthcare model proven in the Korean medical field into the global healthcare market.”

Digital healthcare company Mezoo held a press conference on the 9th at the Conrad Hotel in Yeouido, Seoul, where it presented its future strategy and vision following its KOSDAQ listing. The event was attended by the CEO and key executives of the company.

Founded in 2007 by biomedical engineering PhDs from Yonsei University’s Wonju campus, Mezoo is a digital healthcare company whose core strengths lie in precision biosignal measurement technology and on-device biosignal processing technology.

All founding members of Mezoo, including CEO Park Jung-hwan, specialized in biomedical engineering at Yonsei University. Based on their deep understanding of clinical environments and expertise in interpreting medical device standards, the company possesses strong biomedical engineering–based design capabilities.

The expertise of this specialist group enabled product designs that accurately reflected the requirements of real clinical environments from the early stages of research and development (R&D). As a result, Mezoo has been able to provide next-generation remote monitoring solutions optimized for both healthcare professionals and patients based on its biomedical engineering expertise.

CEO Park stated, “After developing medical systems for more than 20 years, we recognized that there are many blind spots in hospital environments.” He added, “To address these gaps in healthcare coverage as much as possible, we developed and commercialized the platform.”

source : https://www.ebn.co.kr/news/articleView.html?idxno=1701847